KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $5.3 million.

  • Ionis Pharmaceuticals' Capital Expenditures fell 41.81% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.6 million, marking a year-over-year increase of 193.45%. This contributed to the annual value of $45.3 million for FY2024, which is 90.21% up from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Capital Expenditures stood at $5.3 million, which was down 57.17% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Capital Expenditures ranged from a high of $25.5 million in Q4 2024 and a low of -$819,000 during Q4 2023.
  • Over the past 3 years, Ionis Pharmaceuticals' median Capital Expenditures value was $9.1 million (recorded in 2024), while the average stood at $9.0 million.
  • In the last 5 years, Ionis Pharmaceuticals' Capital Expenditures tumbled by 119.79% in 2023 and then spiked by 3,213.19% in 2024.
  • Ionis Pharmaceuticals' Capital Expenditures (Quarterly) stood at $2.5 million in 2021, then surged by 65.43% to $4.1 million in 2022, then tumbled by 119.79% to -$819,000 in 2023, then soared by 3,213.19% to $25.5 million in 2024, then crashed by 41.81% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $12.3 million for Q2 2025, and $12.6 million during Q1 2025.